<DOC>
	<DOCNO>NCT00409656</DOCNO>
	<brief_summary>Most high risk keratoplasty currently perform systemic immunosuppression . Immunosuppressants currently either Cyclosporine A mycophenolate mofetile , administer around 6 month . Due potentially severe adverse effect , new immunosuppressive exerting less side effect would desirable . Basiliximab monoclonal , chimeric antibody , target specifically Interleukin-2-Rezeptor activate T-cells . This agent know specifically inhibit T-cell proliferation upon intravenous application twice follow transplantation . Basiliximab already demonstrate effective kidney transplantation . This investigation prospective , randomized clinical trial orthotopic , high-risk penetrating keratoplasty . Basiliximab evaluate systemic Cyclosporine A . Primary endpoint graft rejection . Secondary endpoint clear graft survival .</brief_summary>
	<brief_title>Prospective , Randomized Trial Basiliximab ( Simulect ) Prophylaxis High-Risk Keratoplasty Patients</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>high risk keratoplasty normal risk keratoplasty</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>